Toshiba shows PowerVision cardiac systems
Toshiba America Medical Systems showcased two models of cardiac ultrasound systems, members of the company’s PowerVision family, at this year’s American College of Cardiology convention in March. The PowerVision 6000 was released two years ago
Toshiba America Medical Systems showcased two models of cardiac ultrasound systems, members of the companys PowerVision family, at this years American College of Cardiology convention in March.
The PowerVision 6000 was released two years ago and the PowerVision 8000 was released at the Radiological Society of North Americas annual meeting last year. A combination of hardware and software allows both systems to perform head-to-toe scanning using a number of applications, including contrast agents, harmonic tissue imaging, and digital imaging.
The difference between the two systems lies in the number of channels, said Scott Yarde, Toshibas ultrasound marketing manager. The 6000 model has 256 channels and the 8000 model has 512 channels.
In addition to plug-and-play transducers, the PowerVision 8000 contains an integrated digital information system package that Tustin, CA-based Toshiba has named PowerView. The PowerView package supports all DICOM service classes and stress echo software. Three-dimensional capabilities and live digital video streaming for telemedicine are being developed.
Clinicians can purchase the PowerView package as an option for the 6000 model. Both systems are capable of quantifying blood flow and perfusion, but these studies have yet to be widely used, Yarde said. The PowerVision 8000 is most appropriate for large, multidepartment hospitals, he said.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
